InspireMD (InspireMD) Cash-to-Debt : 24.47 (As of Dec. 2023)

View and export this data going back to 1997. Start your Free Trial

What is InspireMD Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. InspireMD's cash to debt ratio for the quarter that ended in Dec. 2023 was 24.47.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, InspireMD could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for InspireMD's Cash-to-Debt or its related term are showing as below:

NSPR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.62 Med: 10.03 Max: No Debt
Current: 24.47

During the past 13 years, InspireMD's highest Cash to Debt Ratio was No Debt. The lowest was 0.62. And the median was 10.03.

NSPR's Cash-to-Debt is ranked better than
80.63% of 862 companies
in the Medical Devices & Instruments industry
Industry Median: 2.03 vs NSPR: 24.47

InspireMD Cash-to-Debt Historical Data

The historical data trend for InspireMD's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

InspireMD Cash-to-Debt Chart

InspireMD Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

5.43

9.04

28.34

11.03

24.47

InspireMD Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															11.03	8.60	33.86	27.58	24.47

Competitive Comparison of InspireMD's Cash-to-Debt

For the Medical Devices subindustry, InspireMD's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InspireMD's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, InspireMD's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where InspireMD's Cash-to-Debt falls into.

InspireMD Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

InspireMD's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	39.023	/	(0.557	+	1.038)
	=	24.47

InspireMD's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	39.023	/	(0.557	+	1.038)
	=	24.47

InspireMD (NAS:NSPR) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

InspireMD Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of InspireMD's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

InspireMD (InspireMD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » InspireMD Inc (NAS:NSPR) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

4 Menorat Hamaor Street, Tel Aviv, ISR, 6744832

Website

https://www.inspiremd.com

InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Germany, Italy, Belarus, Brazil, and other countries.

Executives

Gary S Roubin	director	4300 ROCKMORE RD JACKSON, WYOMING WY 83001
Patrick Verta	officer: EVP Clinical/Medical Affairs	12988 VALLEY VIEW ROAD, EDEN PRAIRIE MN 55344
Michael Berman	director	735 PALAMAR AVENUE, SUNNYVALE CA 94085
Thomas J Kester	director	C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Paul Stuka	director	C/O OSIRIS PARTNERS, LLC, ONE LIBERTY SQUARE, 5TH FLOOR, BOSTON MA 02109
Andrea Tommasoli	officer: Chief Operating Officer	22, RUE DE LA PLAGE, COLLONGES AU MONT D OR I0 69660
Shane Thomas Gleason	officer: VP Global Marketing	18 NORTHAMPTON PL, COTO DE CAZA CA 92679
Kathryn Arnold	director	1136 CHESTNUT AVE., WILMETTE IL 60091
Marvin Slosman	director, officer: CEO and President	4 MENORAT HAMAOR ST., C/O INSPIREMD, INC., TEL AVIV L3 6744832
Isaac Blech	director	C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Agustin V Gago	officer: EVP, Chief Commercial Officer	256 JERUSALEM AVE, MASSAPEQUA NY 11758
Eric L. Olson	officer: VP of Global Sales Operations	C/O INSPIREMD, INC., 800 BOYLSTON STREET, 16TH FLOOR, BOSTON MA 02199
Campbell Rogers	director	C/O INSPIREMD, INC., 800 BOYLSTON STREET, SUITE 16041, BOSTON MA 02199
James J Barry	director	C/O INSPIREMD, INC., 4 MENORAT HAMAOR ST., TEL AVIV L3 6744832
Eyal Weinstein	director	C/O LEOREX LTD., P.O.B. 15067 MATAM, HAIFA L3 31905